Featured Research

from universities, journals, and other organizations

Brain estrogen shows promise as schizophrenia treatment

Date:
March 31, 2010
Source:
Monash University
Summary:
An estrogenic drug that influences neurotransmitter and neuronal systems in the brain is showing promise as an effective therapy for women who suffer from schizophrenia.

An estrogenic drug that influences neurotransmitter and neuronal systems inthe brain is showing promise as an effective therapy for women who suffer from schizophrenia.

A study has found that Raloxifene -- a synthetic estrogen currently used to treat osteoporosis -- has beneficial effects on postmenopausal women with schizophrenia, with a test group experiencing a more rapid recovery from psychotic and other symptoms compared to control groups.

Research project leader and Director of the Monash Alfred Psychiatry Research Centre (MAPrc) Professor Jayashri Kulkarni said women in the trial who were given 120mg a day of the unique selective estrogen receptor modulator had a significantly greater improvement in psychosis symptoms compared with those on placebos and lower doses.

"The results were very promising. Under daily treatment with this 'brain estrogen', the women in the study had improvement in their key psychosis symptoms and also experienced enhanced memory and higher learning capacity," Professor Kulkarni said.

"Many patients in this study had longstanding, persistent schizophrenia, so we are delighted that they experienced improvements in their mental well-being. We will continue to investigate the efficacy of Raloxifene which is a currently available treatment for osteoporosis in postmenopausal women."

"Unlike estradiol, the standard estrogen found in the oral contraceptive pill or hormone replacement treatment, this type of estrogen did not have the side effects on breast, uterus and ovarian tissue that we worry about with other forms," Professor Kulkarni said.

While the findings were still tentative given the relatively small sample size, the research team is cautiously optimistic that ongoing trials will further confirm the positive therapeutic potential of the drug for postmenopausal women, and potentially for other cohorts.

Professor Kulkarni said the findings, published in Psychoneuroendocrinology, would offer hope to the hundreds of thousands of women in Australia who suffer from schizophrenia.

"Our results indicate that this therapy really could revolutionise treatment options for women with schizophrenia. While at this stage we are just investigating its use in postmenopausal women, we are planning further research using hormone treatments in younger women and men suffering from psychotic illnesses," Professor Kulkarni said.

"One in five of us will experience a mental illness at some point in our lives. These conditions have a huge impact not only the sufferer, but on their families and Australian communities, so it is critical that governments and the private sector invest in research to develop effective treatment options."

Professor Kulkarni pioneered research into hormonal factors and treatments in psychosis after assessing epidemiological studies that indicated gender differences in the age and onset of schizophrenia, and from clinical observations that symptoms were more severe in women during premenstrual, perimenopausal and postnatal phases. The current study follows on from previous trials of estrogen and anti-estrogen treatment for women and men with a variety of mental illnesses.


Story Source:

The above story is based on materials provided by Monash University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jayashri Kulkarni, Caroline Gurvich, Stuart J. Lee, Heather Gilbert, Emmy Gavrilidis, Anthony de Castella, Michael Berk, Seetal Dodd, Paul B. Fitzgerald, Susan R. Davis. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology, 2010; DOI: 10.1016/j.psyneuen.2010.01.014

Cite This Page:

Monash University. "Brain estrogen shows promise as schizophrenia treatment." ScienceDaily. ScienceDaily, 31 March 2010. <www.sciencedaily.com/releases/2010/03/100330092811.htm>.
Monash University. (2010, March 31). Brain estrogen shows promise as schizophrenia treatment. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2010/03/100330092811.htm
Monash University. "Brain estrogen shows promise as schizophrenia treatment." ScienceDaily. www.sciencedaily.com/releases/2010/03/100330092811.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins